510(k) Report

De Novo · Granted

Granted

Brainsway Deep Transcranial Magnetic Stimulation (DTMS) System

DEN170078De NovoGranted Aug 17, 2018322-day reviewClass II21 CFR 882.5802

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Brainways, Ltd. · QCI Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder

Granted on Aug 17, 2018 as a new device type through De Novo after a 322-day review. 28 later devices descend from it.

Decided
Aug 17, 2018
Review
322 days
Class
Class II
Product code
QCI
Recalls
None

28 later devices descend from it, 3 citing it directly.

Descendants, by year cleared 2019: 1 descendant cleared2020: 2 descendants cleared2024: 3 descendants cleared2023: 7 descendants cleared2022: 1 descendant cleared2025: 7 descendants cleared2021: 1 descendant cleared2026: 6 descendants cleared201620182020202220242026
  1. This deviceDEN170078 Brainsway Deep Transcranial Magnetic Stimulation (DTMS) SystemBrainways, Ltd. · 2018
  2. Descendant · cites it directly · 25 of its ownK183303 Brainsway Deep TMS SystemBrainsway, Ltd. · 2019
  3. Descendant · cites it directly · 24 of its ownK193006 MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS…Tonica Elektronik A/S · 2020
  4. Descendant · 2 generations on · 19 of its ownK212289 NeuroStar Advanced Therapy for adjunctive treatment of OCD…Neuronetics, Inc. · 2022
  5. Descendant · 3 generations on · 13 of its ownK230029 NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023
  6. Descendant · 4 generations on · 7 of its ownK231926 NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · Recalled

Showing 5 of 28 descendants. See all descendants

Descendants cleared per year

2019: 12020: 22021: 12022: 12023: 72024: 32025: 72026: 6
2019high 7 (2023) · low 1 (2019)2026

Most influential descendants

Showing 5 of 28 · See all
  • K183303Brainsway Deep TMS SystemBrainsway, Ltd. · 2019 · cites it directly25descendants
  • K193006MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy systemTonica Elektronik A/S · 2020 · cites it directly24descendants
  • K212289NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced Therapy…Neuronetics, Inc. · 2022 · 2 generations on19descendants
  • K230029NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023 · 3 generations on13descendants
  • K231926NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · 4 generations on7descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN170078Brainsway Deep Transcranial Magnetic Stimulation (DTMS) SystemBrainways, Ltd.2018—
+1K183303Brainsway Deep TMS SystemBrainsway, Ltd.2019—
+1K193006MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy systemTonica Elektronik A/S2020—
+2K212289NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced…Neuronetics, Inc.2022—
+3K230029NeuroStar Advanced Therapy System (Version 3.7)Neuronetics2023—
+4K231926NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc.20241

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201910
202020
202110
202210
202370
202430
202570
202660
FIG. 1 — Lineage of DEN170078, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QCI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QCI device

  1. #1 K212289 NeuroStar Advanced Therapy for adjunctive…score 17.7 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (28)

See all 28

3 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K183303Brainsway Deep TMS SystemBrainsway, Ltd.201925
K193006MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy systemTonica Elektronik A/S202024
K200957Brainsway Deep TMS SystemBrainsway, Ltd.20201

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K183303 (Brainsway, Ltd., 2019) has gone furthest, with 25 descendants of its own.

How does its category compare?

All QCI devices

QCI Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · QCI

1in 2025

2018: 12019: 12020: 12022: 12023: 32024: 12025: 1
2007high 3 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QCI

30in 2023

2023: 30 days median
2007high 30 (2023)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QCI

No recall names QCI since 2007.

Adverse event reports per year · QCI

2in 2024

2019: 12021: 52022: 22024: 2
2007high 5 (2021) · low 0 (2007)2025

MAUDE reports naming product code QCI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20181—00
20191—01
20201—00
20210—05
20221—02
202333000
20241—02
20251—00
20260—0—

What is it indicated for?

The Brainsway Deep Transcranial Magnetic Stimulation System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN170078: Brainsway Deep Transcranial Magnetic Stimulation (DTMS) System.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN170078

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026